The ZOHé study showed that Zarzio is readily used for prophylaxis of chemotherapy-induced neutropenia in France, and clinicians' assessment of febrile neutropenia risk is driven by patient factors more than the EORTC risk category of the chemotherapy regimen. Maintenance of dose intensity was high, especially in patients with non-Hodgkin lymphoma at high risk of neutropenia. Zarzio safety profile was confirmed. Background: The ZOHé study was a prospective, observational, multicenter study in France to assess use of biosimilar filgrastim Zarzio in routine clinical practice in patients undergoing neutropenia-inducing chemotherapy. Patients and Methods: Patients ! 18 years undergoing chemotherapy for a malignant disease and with a first prescription for Zarzio were enrolled in 2 cohorts: solid tumor (1174 patients) or hematological malignancy (633 patients); the latter is reported here. Analyses primarily described the prescription and use of Zarzio in current practice, and included identification of factors linked to prescription for primary prophylaxis, comparison of use in relation to European Organisation for the Research and Treatment of Cancer (EORTC) guidelines, and estimation of chemotherapy dose intensity maintenance in patients given Zarzio. Results: Use of Zarzio in clinical practice was relatively standardized and followed label indication in 96.7% of the analysis population (633 patients). Most patients had ! 2 EORTC patient-related risk factors for febrile neutropenia (FN). Chemotherapy dose intensity was maintained in 85.2% of evaluable patients and 89.6% of patients with non-Hodgkin lymphoma receiving R-CHOP (rituximab-cyclophosphamide/doxorubicin/vincristine/prednisone). The safety profile of Zarzio was confirmed. Conclusions: In routine clinical practice in France, Zarzio is mostly used as primary prophylaxis for chemotherapy-induced neutropenia in patients with hematological malignancies. Patient-related risk factors appear to have more weight in clinicians' decisions to give Zarzio than the FN risk category of the chemotherapy regimen alone in real-world practice.
Introduction
Patients treated with cytotoxic chemotherapy for hematological malignancies (HM) are at risk of developing chemotherapy-induced neutropenia and febrile neutropenia (FN), which are potentially lifethreatening. Administration of granulocyte colony-stimulating factors (G-CSF) has been shown to reduce the incidence of chemotherapy-induced neutropenia, the duration of hospitalization, neutropenia, fever recovery time, and/or antibiotic use in patients receiving standard and intensive doses of chemotherapy. [1] [2] [3] [4] G-CSF is also used for maintenance of chemotherapy dose intensity, which has been associated with improved survival and reduced mortality in HM, 5, 6 especially non-Hodgkin lymphoma (NHL). 7 Recommendations for G-CSF use were defined in guidelines set up by the European Society for Medical Oncology (ESMO), the European Organisation for the Research and Treatment of Cancer (EORTC), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN). The most recent updates were issued in 2010 for ESMO 8 and EORTC, 9 2015 for ASCO, 10 and 2016 for NCCN. 10, 11 The guidelines all recommend G-CSF prophylaxis where a risk of FN due to the chemotherapy protocol is ! 20%, and for patients with intermediate risk (10%-20%) who have additional risk factors (mainly age ! 65 years, advanced stage of the disease, previous episode[s] of FN, low performance status, and comorbidities). Since the most recent EORTC update, numerous anticancer agents and new chemotherapy combinations have been developed and brought into routine clinical practice, especially in hematology, and the FN risk of these agents is not always known. Filgrastim was the first recombinant human G-CSF used in clinical practice, and since 2008, biosimilar versions have been available in Europe. Zarzio (Sandoz GmbH, Holzkirchen, Austria) is a filgrastim biosimilar with demonstrated equivalence in clinical safety and efficacy in Phase 1 and Phase 3 studies to the reference product (Neupogen). [12] [13] [14] [15] [16] Extensive long-term data on its safety and efficacy in clinical practice have been collected. [17] [18] [19] The ZOHé study evaluated the use of Zarzio by oncologists and hematologists to manage the neutropenic risk of chemotherapy in routine practice in France. This article reports the results for the cohort of patients with HM.
Patients and Methods

Study Design
ZOHé was a prospective, noninterventional, longitudinal, national, multicenter study, describing biosimilar filgrastim (Zarzio; Sandoz) use by oncologists and hematologists in routine practice for patients receiving chemotherapy for solid tumors or HM. Ethical approval and data protection approval of the ZOHé study was authorized by the Comité Consultatif sur le Traitement d'Information en matière de Recherche dans le domaine de la Santé and the Commission Nationale de l'lnformatique et des Libertés. Informed patient consent was obtained before study participation. This study was conducted according to the current revision of the 1964 Helsinki declaration.
A total of 1816 patients (637 with HM) were recruited consecutively across 125 sites in France between June 2013 and April 2014. Baseline patient characteristics and data regarding Zarzio prescription were collected at visit 1, on the first day of the chemotherapy cycle in which Zarzio was initiated. Data on the use of Zarzio, patient clinical status, and occurrence of neutropenia and adverse events (AEs) were collected at visit 2, 3 months after inclusion or on discontinuation of chemotherapy or Zarzio if this occurred earlier. A supplemental questionnaire on the administration of chemotherapy was also completed at visit 2 to estimate maintenance of dose intensity.
Data were collected using an electronic case report form and monitored centrally for quality control; AEs were coded using version 17.0 of the Medical Dictionary for Regulatory Activities. Obligatory fields, drop-down lists, and consistency controls verified immediately on data entry were set up to limit missing or incoherent data.
Patients
Patients 18 years or older undergoing cytotoxic chemotherapy for solid tumors or HM who had a first prescription for biosimilar filgrastim Zarzio and who consented to take part in the study were included. This article presents results from the HM cohort of ZOHé.
Primary and Secondary Objectives
The primary objective was to describe indications and use of biosimilar filgrastim Zarzio in routine clinical practice in patients receiving chemotherapy for HM. The study also aimed to describe the characteristics of patients treated with Zarzio, and estimate the proportion of patients whose chemotherapy dose intensity was maintained over the course of their regimen.
Statistical Methodology
To have a precision of 5% with a confidence interval of 95% for the descriptive study objectives, the number of patients required was calculated to be approximately 1830, for a fixed alpha risk of 5% and a reference proportion of 50%, and taking incomplete files into account.
Descriptive statistics and univariate and multivariate comparative analyses were carried out using the SAS package (version 9.4; SAS Institute, Cary, NC). The threshold of significance of comparative analyses was fixed at 5%. For univariate analyses, the association between qualitative variables was tested using the Pearson c 2 test and, for theoretical frequencies < 5, values were regrouped or Fisher exact test performed. Mean values of quantitative variables were compared between groups using Student t test. Imputation of missing data was not carried out for the analyses.
The average relative dose intensity (ARDI) was calculated at each cycle as the total dose of chemotherapy administered during a cycle divided by the total dose scheduled for the same cycle. 20 The chemotherapy dose administered was calculated during each cycle as mg/m 2 /unit of time using data from the follow-up questionnaire. Dose intensity was considered maintained for ratios ! 85%.
Results
Study Population
Of the 1807 patients included in the ZOHé analysis population, 633 (35%) received chemotherapy for HM (Supplemental Figure 1 in the online version). Patients who withdrew before the 3-month follow-up are detailed in Supplemental Table 1 in the online version; most (72.8%, n ¼ 59) were due to completion or discontinuation of chemotherapy or Zarzio. Maintenance of chemotherapy dose intensity was estimated in 420 patients (66.4% of the analysis population) who had evaluable data from the supplementary questionnaire.
Patient Demographics and Clinical Characteristics
Baseline patient characteristics are shown in Table 1 . Two-thirds of patients in the HM cohort had NHL (64.6%, n ¼ 409). A complete list of HM is given in Supplemental Table 2 in the online version.
The mean age of the overall HM cohort was 64.2 AE 16.1 years, although the patients with Hodgkin lymphoma (HL) were younger, with a mean age of 45.5 AE 18.2 years. At inclusion, 10.7% (n ¼ 68) of the HM cohort had a prior episode of severe neutropenia (grade 3 or 4; Table 1 ).
Chemotherapy planned at inclusion (Table 1 ) was first line in 82.9% of patients; of those who were receiving salvage therapy following relapse, most (82.6%) were on at least their second line of salvage chemotherapy. Planned chemotherapy regimens are shown grouped by regimen type and malignancy type in Table 1 . Most patients in each malignancy group were prescribed a chemotherapy regimen classed as high (> 20%) or intermediate (10%-20%) risk for FN in EORTC guidelines. 9 
Zarzio Administration and Treatment Patterns
Zarzio use is detailed by subgroup of HM in Table 2 . Its use was predominantly in accordance with the label indication for established cytotoxic chemotherapy. 12 The median day of administration was day 6 of the current chemotherapy cycle for the NHL and HL groups, and day 7 for "other HM" group. The median duration of planned Zarzio treatment was 5 days per cycle for patients with HL and other HM, and 6 days for patients with NHL; 66.5% of patients who were followed up (n ¼ 409/615) received Zarzio for 4.5 to 6.5 days, and 24.9% received Zarzio for > 6.5 days, including 3 (0.5%) treated for > 14 days. Most patients who were followed up received a mean dose of 30 million international units (MIU) per cycle (78.7%) throughout the course of their treatment, with 20.5% receiving a mean dose of 48 MIU per cycle.
In ZOHé, prophylaxis with G-CSF was considered primary if it occurred during cycle 1 of the current course of chemotherapy at study inclusion, regardless of the intended protocol and day of Zarzio initiation. Zarzio was prescribed as primary prophylaxis in 67.6% of all patients with HM (n ¼ 427), and with curative intent or as secondary prophylaxis in the remainder (32.5%, n ¼ 206). This treatment pattern was consistent across the subgroups: 69.4% of 409 patients with NHL, 72.4% of 87 patients with HL, and 58.4% of 137 patients with "other HM" were given Zarzio as primary prophylaxis.
Zarzio was administered for a median of 4 cycles of chemotherapy across the cohort. Treatment stayed constant for subsequent cycles in most patients (89.6%); in the 64 patients who had their treatment modified, this was mostly a change to the treatment duration (82.8%; n ¼ 53). Overall, 28.6% (n ¼ 176) of patients stopped Zarzio treatment before the end of the study, mostly due to cessation of chemotherapy. Eight patients stopped Zarzio treatment as a result of AEs linked to Zarzio (Table 2) . 
Patterns of Real-World Zarzio Use for Patients With Hematological Malignancies in France
Estimated Maintenance of Chemotherapy Dose Intensity Dose intensity was estimated by comparing the actual doses received with doses planned by the investigator before start of treatment, and was considered to have been maintained (total ARDI ! 85%) in 85.2% of the evaluable patients with HM. Maintenance of dose intensity was similar in all subgroups: 86.5%, 85.7%, and 81.6% of patients with NHL, HL, and other HM, respectively. ARDI was high in the overall cohort (mean AE SD total ARDI 93.9 AE 24.4) and across the subgroups of NHL, HL, and "other HM" (mean total ARDI 94.1, 95.8, and 92.4, respectively).
Use of Zarzio in Relation to Guidelines
The FN risk of patients was assessed in terms of guidelines for FN risk according to the risk of their chemotherapy regimen and patient-related risk factors from EORTC recommendations, 9 and is shown in Table 3 . Where the EORTC recommendations did not provide a risk category for a particular regimen, ASCO 2015 10 and NCCN 2016 11 guidelines were checked for this analysis. No patients receiving Zarzio had a chemotherapy regimen in the low-risk (< 10%) category, in line with recommendations. Many patients received chemotherapy regimens whose FN risk was "unknown" (ie, not specified in the guidelines, particularly in the "other HM" subgroup). Almost all patients overall (99.4%, n ¼ 618/622), and all of those with a chemotherapy regimen of unknown FN risk (100%, n ¼ 350), had at least 1 of the additional patient-related FN risk factors listed in the EORTC recommendations. The prevalence of the risk factors is listed in Table 3 , and was similar across the disease subgroups. Clinicians' reasons for giving Zarzio and their assessment of the FN risk of the chemotherapy regimen planned for the patient are shown in Table 4 . Although most clinicians' assessments were aligned to the guideline risk categories given for the chemotherapy regimens, there were some differences. Two-thirds of patients were classed as having a high risk of FN due to their planned chemotherapy regimen (67.0%) compared with 12.8% according to EORTC guidelines (Table 3 ). The reasons clinicians gave for G-CSF prescription (Table 4) were mostly in alignment with risk factors for FN in the EORTC guidelines (Table 3) . Toxicity or intensity of chemotherapy (including maintenance of dose intensity) were given as reasons (in the "other reasons" category) for prescribing Zarzio in 57 patients (9.0%) overall.
Incidence of Neutropenia
Severe (grade 3-4) neutropenia presented in 16.7% (n ¼ 103) of patients followed up during the study and FN in 4.9% (n ¼ 30). Most patients who had an episode of FN were in cycle 1 of their chemotherapy regimen (86.7%, n ¼ 26) and, by definition, receiving primary prophylaxis. The characteristics of the severe neutropenia episodes are described in Figure 1 . Most of the patients who had at least 1 episode of FN had NHL (n ¼ 21); 42.9% of these were receiving R-CHOP (rituximabcyclophosphamide/doxorubicin/vincristine/prednisone) or CHOPlike chemotherapy.
Safety
During the study, a total of 53 AEs reported as associated with Zarzio occurred in 4.9% (n ¼ 30) of all patients, none of which were considered serious (detailed in Supplemental Table 3 in the online version). Most AEs were mild (47.6%, n ¼ 20/42) or moderate (40.5%, n ¼ 17/42). Musculoskeletal and connective 
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Discussion
The strength of the ZOHé prospective study was the large sample size (1816 patients in 125 centers across France), enabling successful analysis of all planned endpoints. In this study, prescription and use of Zarzio in routine clinical practice were predominantly compliant with the label indication, and treatment modifications were rarely used. Zarzio was largely used for primary prophylaxis in the first cycle of chemotherapy (67.5% of patients with HM).
Patients being treated for HM who are given Zarzio tend to be older (mean age 64.2 years; 42.2% ! 70 years), except for patients with HL (mean age 45.5 years), and to have advanced metastatic disease (61.6% stage III or IV) but a good performance status (95.6% Eastern Cooperative Oncology Group Performance Status 0-2). Other EORTC risk factors for FN that were common in these Table 3 
Patients with chemotherapy regimen in EORTC FN risk category, n (%) Few AEs related to Zarzio were reported during the study, the most frequent being muscular and/or bone pain, confirming the safety profile of this biosimilar filgrastim. No unexpected AEs were seen in patients included in the analysis.
Numerous chemotherapy protocols were recorded for the patients included in the study, which reflects the diversity of HM, disease stage, aims of the chemotherapy course, and the practices of the participating centers. Most patients received a chemotherapy protocol for which G-CSF support is recommended to reduce neutropenia and maintain dose intensity. 9 Most patients in ZOHé were able to maintain the dose intensity of their chemotherapy regimen during the follow-up period, allowing them to gain the full benefit of their chemotherapy with potential improvements in mortality. 5, 6, 21, 22 Patients with NHL receiving R-CHOP/CHOPlike chemotherapy, who were at high risk of FN both from their disease 23 and the chemotherapy protocol, maintained a high ARDI, despite having factors known to reduce ARDI (ie, older age and advanced disease) 24 similar to that described elsewhere for realworld use of Zarzio. 18 Maintenance of dose intensity is critical in those patients who are receiving chemotherapy with curative intent. The ZOHé study suggests that, in real-world practice, clinicians predominantly give Zarzio to patients they consider to be at high risk of neutropenia, either due to their chemotherapy regimen and/ or a combination of risk factors due to patient characteristics. 9, 10 However, many of the chemotherapy regimens used in clinical practice do not have an FN risk category in the guidelines. With these patients, clinicians must rely on the patient-related risk factors to guide their decision to prescribe G-CSF support. Most patients in the HM cohort of ZOHé (76.0%, n ¼ 473/622) had 2 to 3 patient-based risk factors for increased incidence of FN, which, along with the ! 10% FN risk intrinsic to HM, 23 most likely underlies the clinicians' decision to prescribe primary prophylaxis. The need for G-CSF support to maintain dose intensity in patients with HM who are given chemotherapy with curative intent could also underlie clinicians' use of Zarzio.
In the MONITOR-GCSF study of real-world Zarzio treatment patterns and FN incidence across 12 countries, including France, 26% of patients were given Zarzio as primary prophylaxis despite being below the risk threshold for such treatment according to EORTC guidelines, 19 suggesting that G-CSF prophylaxis in routine practice is much more readily used than the EORTC guidelines envisage. Although earlier studies found that G-CSF prophylaxis for chemotherapy-induced neutropenia was underused in European real-world practice, 25, 26 more recent studies suggest that the widespread availability and reduced cost of biosimilar G-CSFs is leading to increased use in clinical practice. 17, 27, 28 Limitations of the current study include selection bias, recall bias, and the need to pool data. Selection bias is inherent to the voluntary participation in this observational study, and was addressed by recruiting physicians such that the sample of investigators recruited reflected the practices of physicians throughout France, by including patients sequentially and limiting the number of patients to 35 for each site. The need to group chemotherapy protocols by category and treatment stage to assess the results limited the overall interpretations of the individual clinical situations. The assessment of maintenance of dose intensity is limited by being based on self-assessed data completed for all cycles at the final visit, which was potentially subject to recall bias on the part of the investigators. 
Conclusions
The ZOHé study was a large observational study of Zarzio use in routine clinical practice in France in patients undergoing chemotherapy for HM. Zarzio use is relatively standardized, regardless of malignancy and variations in patient characteristics, and compliant with the label indication. In patients with HM, Zarzio was most commonly used as primary prophylaxis. Incidences of FN and AEs were low and in keeping with previous studies of Zarzio. Maintenance of dose intensity was high, particularly in patients with NHL receiving R-CHOP/CHOP-like chemotherapy regimens, and in line with other real-world studies, such as MONITOR-GCSF. 19 Patient-based risk factors for neutropenia appear to have more weight in clinicians' decisions to use Zarzio in real-world practice than the guideline risk category of the chemotherapy regimen.
Clinical Practice Points
Guidelines for G-CSF in support of chemotherapy recommend its use based on assessment of FN risk factors developed from clinical trial data, but large-scale data on the use of G-CSF in routine clinical practice, given the many new chemotherapy regimens and targeted drugs coming into use, and widespread availability of biosimilars, are lacking. For clinicians in France, patient risk factors appear to be the main driver of the decision to prescribe Zarzio, rather than the risk category of the chemotherapy regimen. Use of Zarzio in routine clinical practice enabled a high proportion (90%) of patients with NHL receiving R-CHOP or CHOP-like regimens to maintain the dose intensity necessary for chemotherapy with curative intent.
